peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

Somatostatin analog · octapeptide

Octreotide

/ok-TREE-oh-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Sandostatin

Subcutaneous or intravenous injection

Selected acromegaly and severe secretory diarrhea syndromes.

Find official label ↗
02

Sandostatin LAR Depot

Long-acting intramuscular depot

Maintenance treatment in product-specific indications.

Find official label ↗
03

Mycapssa

Delayed-release oral capsule

Maintenance treatment in selected acromegaly patients.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Suppresses growth hormone and multiple gastrointestinal/pancreatic hormones through somatostatin receptors.Mechanism source
Labeled-use boundary
Indication and transition instructions depend heavily on immediate-release, depot, or oral formulation.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Who should avoid it

  • Serious hypersensitivity; additional restrictions are product-specific
Contraindications

More common effects

  • Gallbladder abnormalities
  • Diarrhea
  • Abdominal pain
  • Nausea
  • Injection-site pain
  • Headache
Adverse reactions

Important serious risks

  • Cholelithiasis and complications
  • Glucose dysregulation
  • Bradycardia and conduction abnormalities
  • Thyroid function changes
  • Nutrient malabsorption
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

Hormone suppression

Biochemical response is measurable across GH and selected tumor-secreted hormones.

Supporting source
Evidence form
Established clinical pharmacology
Keep in view
Biochemical control and symptom control are not identical outcomes.
02

Formulation-dependent exposure

Immediate, depot, and oral forms create materially different treatment pathways.

Supporting source
Evidence form
Product-specific trials
Keep in view
Transition requires the applicable label.
03

Multisystem safety

Gallbladder, glucose, thyroid, cardiac, and absorption effects require a broad safety view.

Supporting source
Evidence form
Regulatory synthesis
Keep in view
Risks vary with comorbidity and duration.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Sandostatin prescribing information

    Current DailyMed immediate-release octreotide label.

    Open source ↗
  2. 02Literature index
    Every PubMed result for octreotide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for octreotide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    octreotide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗